Treatment Information

Back

Colon Cancer treatment details. Chemotherapy.

Hospital Universitario Central de Asturias, Oviedo, Spain.

Survival: monthsCountry:Spain
Toxiciy Grade:3City/State/Province:Oviedo
Treatments:ChemotherapyHospital:Hospital Universitario Central de Asturias
Drugs:Journal:Link
Date:Oct 2011

Description:

Patients:
This study involved colorectal cancer patients who had progressed after previous chemotherapy. Patients were separated into two separate treatment groups. Group A had 38 patients, 24 of whom were male, with a median age of 63.5 years. There were 38 patients with a median age of 65 years in group B; 22 of these were male.

Treatment:
Patients in group A were treated with a combination of the chemotherapy agents raltitrexed and gefitinib.

Patients in Group B received the chemotherapy agent raltitrexed alone.

Toxicities:
The most severe toxicities in group A were of grade 3 and included liver enzyme deregulation, anorexia, diarrhea, and weakness.

The most severe toxicity in group B was one grade 4 kidney failure. Grade 3 liver enzyme deregulation, and diarrhea were also reported.

Results:
The median overall survival times for group A and B were 11.9 and 9.6 months, respectively.

Support:
This study was supported by AstraZeneca, makers of raltitrexed (brand name: Tomudex).

Correspondence: Dr. José María Viéitez; email: [email protected]



Back